A rare case of propofol-induced acute liver failure and literature review

Case Reports in Gastroenterology

Volumn 4, Issue 1, 2010, Pages 57-65

  Kneiseler, G ^a   Bachmann, H S ^a   Bechmann, L P ^a   Dechene, A ^a   Heyer, T ^b   Baba, H ^a   Saner, F ^a   Jochum, C ^a   Gerken, G ^a   Canbay, A ^a  

^a UNIVERSITY HOSPITAL ESSEN   (Germany)

^b StMarien Hospital Duren   (Germany)

Author keywords

Oxidation; 2,6 diisopropylphenol (propofol); Acute liver failure; Drug toxicity; Free fatty acids; Transient elastography

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; BILIRUBIN; CYTOCHROME P450 2B6; FATTY ACID; GLUCURONOSYLTRANSFERASE 1A9; PREDNISOLONE; PROPOFOL; URSODEOXYCHOLIC ACID;

ADULT; ARTICLE; ASCITES; BLOOD CLOTTING DISORDER; BRAIN DISEASE; CASE REPORT; CAUCASIAN; CELL DEATH; CORTICOSTEROID THERAPY; DIAGNOSTIC IMAGING; DISEASE COURSE; ELASTOGRAPHY; FATTY ACID OXIDATION; FATTY LIVER; FEMALE; GENE SEQUENCE; GENETIC ANALYSIS; GENETIC SUSCEPTIBILITY; GENOTYPE; HEMOCHROMATOSIS; HEPATITIS; HEPATOMEGALY; HETEROZYGOSITY; HOSPITAL ADMISSION; HOSPITAL DISCHARGE; HUMAN; INTERNATIONAL NORMALIZED RATIO; JAUNDICE; LABORATORY TEST; LIVER BIOPSY; LIVER CELL; LIVER DYSFUNCTION; LIVER FAILURE; LIVER FATTY DEGENERATION; LIVER HISTOLOGY; LIVER INJURY; LIVER PARENCHYMA; PRIORITY JOURNAL; VARICOSIS;

EID: 77958597754     PISSN: None     EISSN: 16620631     Source Type: Journal    
DOI: 10.1159/000262448     Document Type: Article

References (38)

1. Lee WM: Acute liver failure in the United States. Semin Liver Dis 2003;23:217-226.
2. Canbay A, Jochum C, Bechmann L, et al: Retrospective study of acute liver failure in residents of a metropolitan area in Germany: Influence of cholestatic enzymes and body mass index on clinical outcome. Z Gastroenterol DOI: 10.1016/S0168-8278(08)60184-60191
3. Kaplowitz N: Biochemical and cellular mechanisms of toxic liver injury. Semin Liver Dis 2002;22:137-144.
4. Zimmerman HJ: Drug-induced liver disease. Clin Liver Dis 2000;4:73-96, vi.
5. Kaplowitz N: Drug-induced liver disorders: implications for drug development and regulation. Drug Saf 2001;24:483-490.
6. Pessayre D, Berson A, Fromenty B, Mansouri A: Mitochondria in steatohepatitis. Semin Liver Dis 2001;21:57-69.
7. Cray SH, Robinson BH, Cox PN: Lactic acidemia and bradyarrhythmia in a child sedated with propofol. Crit Care Med 1998;26:2087-2092.
8. De Cosmo G, Congedo E, Clemente A, Aceto P: Sedation in PACU: the role of propofol. Curr Drug Targets 2005;6:741-744.
9. Fodale V, La Monaca E: Propofol infusion syndrome: an overview of a perplexing disease. Drug Saf 2008;31:293-303.
10. Dechene A, Treichel U, Gerken G: Effectiveness of a steroid-and ursodesoxycholic acid combination therapy with drug-induced subacute liver failure. The Liver Meeting, American Association of Liver Diseases (AASLD) 56th Annual Meeting and Postgraduate Course, November 11-15, 2005, San Francisco, CA, USA, poster 412. Hepatology 2005;42(suppl 1):196A-757A.
11. Sutherland L, Ebner T, Burchell B: The expression of UDP- glucuronosyltransferases of the UGT1 family in human liver and kidney and in response to drugs. Biochem Pharmacol 1993;45:295-301.
12. Court MH, Duan SX, Hesse LM, Venkatakrishnan K, Greenblatt DJ Cytochrome P-450 2B6 is responsible for interindividual variability of propofol hydroxylation by human liver microsomes. Anesthesiology 2001;94:110-119.
13. Yea SS, Lee SS, Kim WY, et al: Genetic variations and haplotypes of UDP-glucuronosyltransferase 1A locus in a Korean population. Ther Drug Monit 2008;30:23-34.
14. Hesse LM, He P, Krishnaswamy S, et al: Pharmacogenetic determinants of interindividual variability in bupropion hydroxylation by cytochrome P450 2B6 in human liver microsomes. Pharmacogenetics 2004;14:225-238.
15. Lang T, Klein K, Fischer J, et al: Extensive genetic polymorphism in the human CYP2B6 gene with impact on expression and function in human liver. Pharmacogenetics 2001;11:399-415.
16. Nguyen HD, Borum ML: Acute hepatitis in a patient given propofol during colonoscopy. South Med J 2009;102:333-334.
17. Polo-Romero FJ, Paricio P, Tovar A, Alonso JM: Propofol-induced acute toxic hepatitis after brief sedation for endoscopic retrograde cholangiopancreatography. Endoscopy 2008;40(suppl 2):E49.
18. Anand K, Ramsay MA, Crippin JS: Hepatocellular injury following the administration of propofol. Anesthesiology 2001;95:1523-1524.
19. Ypsilantis P, Politou M, Mikroulis D, et al: Organ toxicity and mortality in propofol-sedated rabbits under prolonged mechanical ventilation. Anesth Analg 2007;105:155-166.
20. Parke TJ, Stevens JE, Rice AS, et al: Metabolic acidosis and fatal myocardial failure after propofol infusion in children: five case reports. BMJ 1992;305:613-616.
21. Kang TM: Propofol infusion syndrome in critically ill patients. Ann Pharmacother 2002;36:1453-1456.
22. Mehta N, DeMunter C, Habibi P, Nadel S, Britto J: Short-term propofol infusions in children. Lancet 1999;354:866-867.
23. Liolios A, Guerit JM, Scholtes JL, Raftopoulos C, Hantson P: Propofol infusion syndrome associated with short-term large-dose infusion during surgical anesthesia in an adult. Anesth Analg 2005;100:1804-1806.
24. O'Grady JG, Schalm SW, Williams R: Acute liver failure: redefining the syndromes. Lancet 1993;342:273-275.
25. Vasile B, Rasulo F, Candiani A, Latronico N: The pathophysiology of propofol infusion syndrome: a simple name for a complex syndrome. Intensive Care Med 2003;29:1417-1425.
26. Motsch J, Roggenbach J: Propofol infusion syndrome (in German). Anaesthesist 2004;53:1009-1022, quiz 1023-1024.
27. Branca D, Roberti MS, Lorenzin P, Vincenti E, Scutari G: Influence of the anesthetic 2,6-diisopropylphenol on the oxidative phosphorylation of isolated rat liver mitochondria. Biochem Pharmacol 1991;42:87-90.
28. Schenkman KA, Yan S: Propofol impairment of mitochondrial respiration in isolated perfused guinea pig hearts determined by reflectance spectroscopy. Crit Care Med 2000;28:172-177.
29. Wolf A, Weir P, Segar P, Stone J, Shield J: Impaired fatty acid oxidation in propofol infusion syndrome. Lancet 2001;357:606-607.
30. Feldstein AE, Canbay A, Guicciardi ME, Higuchi H, Bronk SF, Gores GJ: Diet associated hepatic steatosis sensitizes to Fas mediated liver injury in mice. J Hepatol 2003;39:978-983.
31. Feldstein AE, Canbay A, Angulo P, et al: Hepatocyte apoptosis and fas expression are prominent features of human nonalcoholic steatohepatitis. Gastroenterology 2003;125:437-443.
32. Simons PJ, Cockshott ID, Douglas EJ, Gordon EA, Hopkins K, Rowland M: Disposition in male volunteers of a subanaesthetic intravenous dose of an oil in water emulsion of 14C-propofol. Xenobiotica 1988;18:429-440.
33. Guitton J, Buronfosse T, Desage M, et al: Possible involvement of multiple human cytochrome P450 isoforms in the liver metabolism of propofol. Br J Anaesth 1998;80:788-795.
34. Oda Y, Hamaoka N, Hiroi T, et al: Involvement of human liver cytochrome P4502B6 in the metabolism of propofol. Br J Clin Pharmacol 2001;51:281-285.
35. Murayama N, Minoshima M, Shimizu M, Guengerich FP, Yamazaki H: Involvement of human cytochrome P450 2B6 in the omega-and 4-hydroxylation of the anesthetic agent propofol. Xenobiotica 2007;37:717-724.
36. Takahashi H, Maruo Y, Mori A, Iwai M, Sato H, Takeuchi Y: Effect of D256N and Y483D on propofol glucuronidation by human uridine 5′-diphosphate glucuronosyltransferase (UGT1A9). Basic Clin Pharmacol Toxicol 2008;103:131-136.
37. Zanger UM, Klein K, Saussele T, Blievernicht J, Hofmann MH, Schwab M: Polymorphic CYP2B6: molecular mechanisms and emerging clinical significance. Pharmacogenomics 2007;8:743-759.
38. Girard H, Court MH, Bernard O, et al: Identification of common polymorphisms in the promoter of the UGT1A9 gene: evidence that UGT1A9 protein and activity levels are strongly genetically controlled in the liver. Pharmacogenetics 2004;14:501-515.